It is a randomized, multicenter, double-blind, placebo controlled, interventional clinical trial that will be conducted in Poland, in about 6 Hospital Nephrology Departments to evaluate the safety and effectiveness of desmopressin on the prevention of bleeding after percutaneous needle kidney biopsy in patients with rare and ultrarare glomerulonephritis.
≥ 18 years old
Ability to provide Informed Consent
Qualification by nephrologist to kidney biopsy in accordance to current standards
Initial haemoglobin concentration > 8g/dl and PLT count >100 x103/μL
Initial sodium concentration <130mmol/l
Pregnancy and breastfeeding
Anaphylactic shock after desmopressin administration (medical history)
Necessity of administration other anti-platelet / anti thrombotic drugs other than acetylsalicylic acid, non-fractionated heparin or low molecular weight heparin